Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib frontline monotherapy for elderly unfit or frail mantle cell lymphoma
2025-521666-10-01Phase 2Authorised
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirtobrutinib in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Progression-free survival. Planned start Feb 2026; status: authorised.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2025-521666-10-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521666-10-01.